Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
MAIA Biotechnology, Inc. (MAIA)
NYSE MKT:MAIA
Holding MAIA?
Track your performance easily
MAIA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.82 - $5.99
Previous Close$2.98
Volume57.22K
Average Volume (3M)275.03K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$11.58M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 06, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding23,907,212
10 Day Avg. Volume52,887
30 Day Avg. Volume275,026
Standard Deviation0.29
R-Squared0.00349
Alpha0.00989
Financial Highlights & Ratios
Price to Book (P/B)20.94
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
MAIA Biotechnology, Inc. News
PremiumCompany Announcements
MAIA Biotechnology Reports Progress in Cancer Drug Development
PremiumCompany Announcements
MAIA Biotechnology Highlights Clinical Progress and Investor Insights
PremiumCompany Announcements
MAIA Biotechnology Unveils Promising THIO-101 Trial Results
PremiumCompany Announcements
MAIA Biotechnology Unveils New Business Overview PresentationOwnership Overview
18.51% Insiders
1.80% Mutual Funds
6.11% Other Institutional Investors
73.58% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MAIA FAQ
What was MAIA Biotechnology, Inc.’s price range in the past 12 months?
MAIA Biotechnology, Inc. lowest stock price was $0.82 and its highest was $5.99 in the past 12 months.
What is MAIA Biotechnology, Inc.’s market cap?
Currently, no data Available
When is MAIA Biotechnology, Inc.’s upcoming earnings report date?
MAIA Biotechnology, Inc.’s upcoming earnings report date is Nov 06, 2024 which is in 74 days.
How were MAIA Biotechnology, Inc.’s earnings last quarter?
MAIA Biotechnology, Inc. released its earnings results on Aug 19, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.415 by $0.015.
Is MAIA Biotechnology, Inc. overvalued?
According to Wall Street analysts MAIA Biotechnology, Inc.’s price is currently Overvalued.
Does MAIA Biotechnology, Inc. pay dividends?
MAIA Biotechnology, Inc. does not currently pay dividends.
What is MAIA Biotechnology, Inc.’s EPS estimate?
MAIA Biotechnology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MAIA Biotechnology, Inc. have?
MAIA Biotechnology, Inc. has 23,907,211 shares outstanding.
What happened to MAIA Biotechnology, Inc.’s price movement after its last earnings report?
MAIA Biotechnology, Inc. reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.415. Following the earnings report the stock price went down -0.338%.
Which hedge fund is a major shareholder of MAIA Biotechnology, Inc.?
Currently, no hedge funds are holding shares in MAIA
---
MAIA Biotechnology, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
MAIA Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.84%
12-Months-Change
Fundamentals
Return on Equity
-559.56%
Trailing 12-Months
Asset Growth
17.05%
Trailing 12-Months
Company Description
MAIA Biotechnology, Inc.
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
---
MAIA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering MAIA
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+15.81%
reiterated a buy rating 6 months ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +15.81% per trade.
---